Differential response to carfilzomib based on initial therapy with bortezomib in multiple myeloma.

Sarvari Venkata Yellapragada,Chizoba Ifeorah,Luke Fletcher,Gustavo A. Rivero,Zahida Yasin,Jordan Krieger,Alka Mulchandani,André Catic,Martha P. Mims

Differential response to carfilzomib based on initial therapy with bortezomib in multiple myeloma.

2017

Sarvari Venkata Yellapragada
Chizoba Ifeorah
Luke Fletcher
Gustavo A. Rivero
Zahida Yasin
Jordan Krieger
Alka Mulchandani
André Catic
Martha P. Mims

e19515Background: Proteasome inhibitors (PIs) are efficacious in multiple myeloma (MM). In randomized phase 3 studies Carfilzomib doubled the progression free survival (PFS) compared to Bortezomib ...

Keywords:

Bortezomib
Physical therapy
Cancer research
Carfilzomib
Medicine
Multiple myeloma
initial therapy
Oncology
Progression-free survival
Internal medicine
Proteasome
Pathology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations